PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰萊 ® ) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational ...
2026-05-22T    Health Care/Hospital   Medical/Pharmaceuticals 
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI , May 22, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310 , a novel bispecific ...
2026-05-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China , May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data ...
2026-05-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations ...
2026-05-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings
SINGAPORE , May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the " Company " or " KBP ") today issued a statement addressing the decision by the Singapore Court of Appeal to ...
2026-05-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). Clinical safety confirmed through COVID-19 and Dengue clinical trials. Class-wide ...
2026-05-21T    Health Care/Hospital   Medical/Pharmaceuticals 
Dimora Medical Launches Advanced Sacrum Silicone Absorbent Dressing to Enhance Pressure Injury Care
NEW YORK , May 21, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, has introduced its new Sacrum Silicone Absorbent Soft Dressing, expanding its portfolio ...
2026-05-21T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026
PARIS , May 20, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, today announced robust 3-month clinical data from its HERO-HTN-FIH study during a featured presentation at EuroPCR ...
2026-05-20T    Health Care/Hospital   Medical/Pharmaceuticals 
Pictor and Disease Research Limited Formalise Collaboration to Advance Johne's Disease Monitoring Across New Zealand
Building on a two-year scientific collaboration and co-authored peer-reviewed publication, the collaboration supports   new approaches   to herd health monitoring for New Zealand's dairy and ...
2026-05-20T    Agriculture   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
NCCN Affirms Commitment to Cancer-Related Distress Resources Worldwide During Mental Health Awareness Month
The latest version of the National Comprehensive Cancer Network's Distress Thermometer and Problem List is available for free in more than 70 languages. ...
2026-05-20T    Education   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.